The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2.
Rogerio Lilenbaum
Research Funding - Lilly
Mauro Zukin
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Jose Rodrigues Pereira
No relevant relationships to disclose
Carlos H. Barrios
No relevant relationships to disclose
Ronaldo De Albuquerque Ribeiro
No relevant relationships to disclose
Carlos Augusto de Mendonça Beato
No relevant relationships to disclose
Yeni Neron do Nascimento
No relevant relationships to disclose
Andre Murad
No relevant relationships to disclose
Fabio A. Franke
No relevant relationships to disclose
Maristela Precivale
No relevant relationships to disclose
Luiz Henrique de Lima Araujo
No relevant relationships to disclose
Clarissa Serodio Da Rocha Baldotto
No relevant relationships to disclose
Fernando Meton Vieira
No relevant relationships to disclose
Isabele Avila Small
No relevant relationships to disclose
Carlos G. M. Ferreira
No relevant relationships to disclose